RELX

RELX Plc

AI '25: Apps & Edge Deployment AI '25: Data Owners AI '25: Money, Risk & Law Applications Alt & Market Data '26: Risk Analytics Software '26: Legal Tech

Loading…

Overview

RELX (UK-based) is a global data, analytics, and publishing company that helps professionals make better decisions. About 35% of revenue comes from Risk (fraud,

RELX (UK-based) is a global data, analytics, and publishing company that helps professionals make better decisions. About 35% of revenue comes from Risk (fraud, identity, insurance analytics sold to banks and insurers), 32% from STM/Elsevier (scientific research tools sold to universities), 20% from Legal/LexisNexis (AI legal research used by law firms and in-house legal teams), and 13% from RX Exhibitions (trade shows for industries). Customers include banks, insurers, law firms, universities, corporations, and event exhibitors—no single buyer dominates sales.

Bull / Bear Details

RELX is a high-quality data & analytics compounder with accelerating AI monetization (Lexis+ AI, STM tools), resilient subscription base, and exhibitions now st

Thesis

RELX is a high-quality data & analytics compounder with accelerating AI monetization (Lexis+ AI, STM tools), resilient subscription base, and exhibitions now structurally stronger post-COVID; strong cash generation supports buybacks/dividends.

Bull case

Legal AI adoption is driving double-digit spend uplift, showing pricing power.
STM article submissions +20% YoY provide a growing content base for monetization.
Exhibitions now growing 7–8% above pre-COVID baseline with margin leverage.

Bear case

Competitive threats (Harvey, Westlaw AI) could erode Legal moat if RELX lags.
STM adoption curve is slower, and open access mandates could pressure growth.
Exhibitions are cyclical; macro weakness or budget tightening could derail momentum.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data
Cash returns & FX	Buybacks/dividends support valuation; FX drives ADR performance	Pace of £1.5bn buyback program, GBP/USD trend	Execution = downside support; FX headwinds mute ADR	LSE RNS feed, Bloomberg/Reuters FX dashboards	Yahoo Finance GBP/USD ticker; daily RNS filings(free via LSE site)
Exhibitions bookings & margins (RX)	7–8% growth seen as “new normal” but cyclical risk	Forward booking commentary, attendance, margin seasonality in H2	Strong bookings = resilient baseline; softness = macro exposure	Company disclosures, trade show industry publications	Exhibitor lists / event websites scrapes (e.g. Comic-Con, RX shows); Google Trends for flagship events
Open access & university funding (STM)	Policy changes could reshape economics; NIH already shifted	NIH/other funding mandates, university renewal budgets	More mandates = revenue model shift; resilience = STM moat	NIH/European Commission sites, academic library consortia reports	Twitter/X chatterfrom academics/publishers; university budget reports (often public PDFs)
Legal AI adoption (Lexis+ AI, Protégé)	Biggest near-term driver of pricing power and revenue acceleration	Penetration rates in new sales & renewals, spend uplift commentary	Strong uptake = durable growth; weak = competitive risk vs. Westlaw AI	Company earnings updates, legal tech media, competitor calls	Google Trends: “Lexis+ AI” vs. “Westlaw AI”; LinkedIn workforce mix in Legal/IT roles
STM AI rollout (ScienceDirect AI, Scopus AI)	Expands TAM; adoption curve slower than Legal	Uptake of AI tools, article submission and publication volumes	Faster adoption = growth acceleration; slower = STM drag	Elsevier announcements, academic publishing news, policy updates	arXiv / PubMed submission counts(open datasets); Elsevier APC pricing pages

Key Reported Metrics3 rows

Metric	Why It Matters	Last Period
Exhibitions growth / bookings	RX rebased at 7–8% growth; resilience is a test of cyclical exposure and new digital tools	'+8% (Q2 2025, same as FY 2024 baseline)
STM segment revenue growth	Elsevier is core cash engine; AI rollout + open access/funding noise make trajectory key	'+5% (Q2 2025, flat vs +5% FY 2024)
Legal segment revenue growth	Lexis+ AI adoption is the biggest driver of incremental growth & pricing power; investors want proof it sustains	'+9% (Q2 2025, up from +8% FY 2024)

Key Questions

Will AI products (Lexis+ AI, ScienceDirect AI, Scopus AI) sustain pricing power and drive faster growth than competitors like Westlaw AI or Clarivate?

Question 2: Can STM continue mid-single digit growth despite open access mandates and university funding pressures?
Question 3: Is Exhibitions' 7–8% growth the new structural baseline, or will macro/marketing budget cycles pull it back down?

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	IS CHANGE	Price Reaction
2025-07-24	Solid quarter with 7% revenue growth and margin gains; Legal AI momentum strong, STM steady, Exhibitions resilient. Stock reaction mixed as print carve-out, policy noise, and AI competition tempered enthusiasm.	Earnings Transcript	Mixed			-1.82% (vs SPY: -2.22%)